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Renal ﬁbrosisIn addition to their role as oncogenes, Ras GTPases are key regulators of cell function. There is a proven relation-
ship between the signaling pathways of transforming growth factor-β1 (TGF- β1) and Ras GTPases. Each of the
Ras isoforms (H, N and K) exhibits speciﬁc modulatory activity on different cellular pathways. Our purpose has
been to study some of the mechanisms involved in the development of renal ﬁbrosis, assessing the individual
role of N-Ras in basal and TGF-β1-mediated extracellular matrix (ECM) synthesis, proliferation, and migration
in immortalized N-Ras deﬁcient ﬁbroblasts (N-ras−/−). Compared to normal counterparts, ﬁbroblasts deﬁcient
for N-Ras exhibited higher basal activity levels of phosphatidylinositol-3-kinase (PI3K)/Akt andMEK/Erk, accom-
panied by upregulated collagen synthesis and diminished proliferation and migration rates. We found that the
absence of N-Ras did not affect TGF-β1-induced proliferation and migration, which required PI3K/Akt but not
Erk1/2 activation. Similar effector pathway dependencewas found for ﬁbronectin and collagen type I expression.
Our results indicate that N-Ras might contribute to renal ﬁbrosis through the down-regulation of ECM synthesis
and up-regulation proliferation and migration modulating Akt activation. N-Ras also regulates TGF-β1-induced
collagen I and ﬁbronectin expression through Erk-independent pathways.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Ras superfamily encompasses more than 150 small GTPases, divided
into at least 5 distinct subfamilies (Ras, Rho/Rac, Rab, Arf, and Ran). The
mammalianRas subfamily, initially described as pro-oncogenes, includes
three ras genes and four 21 kDa proteins highly conserved across differ-
ent species: H-Ras, N-Ras, K-Ras4A and K-Ras4B that play functionally
signiﬁcant roles in numerous cellular processes, including proliferation,
survival and differentiation [1–5]. These Ras proteins are ubiquitously
expressed in all cell lineages and organs, although there are quantitative
and qualitative differences in expression through tissues or development
stage [6,7]. In addition, speciﬁc intracellular processing and localization
in different membrane microdomains or subcellular compartments of
each Ras isoformmay provide further biological basis for isoform speciﬁc
function [6,8–14].β1; ECM, extracellular matrix;
MEK-Erk1/2, mitogen activated
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bound form. Activated Ras isoforms may interact with several effector
pathways, including phosphatidylinositol 3-kinase-protein kinase B
(PI3K-Akt) and MEK/Erk1/2 [15]. Activation of MEK/Erk pathway con-
trols cell-cycle progression, differentiation and apoptosis [16] while
PI3K/Akt pathway is implicated in regulation of cell metabolism, prolif-
eration, cell motility and promotion of cell survival protecting cells from
apoptosis [17].
Transforming growth factor-β (TGF-β), a cytokine involved in extra-
cellular matrix (ECM) homeostasis and control of cell proliferation
[18–23], and Ras signaling pathways have numerous relationships. For
example, during epithelial regeneration TGF-β antagonizes mitogenic
Ras signaling, but in tumor progression TGF-β and Ras act synergistically
[24]. Ras GTPases participate downstream in the signaling of TGF-β, and
share some signal pathways such as PI3K/Akt and MEK/Erk 1/2 [25–29].
Fibroblast proliferation and migration play a major role in the genesis of
renal ﬁbrosis [30] and this can be extended to other models of ﬁbrosis
[31]. There are studies suggesting different functional roles for each Ras
isoform in proliferation, migration and ECM expression [32–34]. Previous
studies of our group have shown that the lack of both H- and N-Ras
isoforms in ﬁbroblasts is associated to increased ECM synthesis and re-
duced ﬁbroblast proliferation [33]. Recently we have also demonstrated
that the H-Ras isoform down-regulates ECM synthesis and stimulates
Fig. 1. Ras activation and expression of Ras effectors, Erk and Akt in WT and N-ras−/−
ﬁbroblasts. Ras-GTP evaluated by ELISA (A); phospho-Erk (B) and phospho-Akt (C)
protein expressions evaluated by Western blot. Histograms in (A) represent the
mean ± standard error of the mean (SEM) of the luminescence of 3 experiments
measured by triplicate, expressed as percentage over basal values (WT ﬁbroblasts
in 0.5% FCS, 100%). Histograms in B and C represent the mean ± SEM of the optical
density of the bands, expressed as percentage over basal values (WT ﬁbroblasts in
0.5% FCS, 100%). Histograms correspond to the ratio phospho-Erk 1/2/Erk 1/2 or
phospho-Akt/Akt expression. Lower panel in B–C shows a representative blot of 42
(WT)-17 (N-ras−/−) experiments, performed under similar conditions. Statistically
signiﬁcant differences: *(p b 0.05) or **(p b 0.01) vs. WT ﬁbroblasts in basal condi-
tions; #(p b 0.01) vs. WT ﬁbroblasts treated with 1 ng/mL TGF-β1.
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tion in ﬁbroblasts [32]. In agreement with these results, in an in vivo
model of obstructive nephropathy in mice we have reported that H-Ras
regulates tubule-interstitial ﬁbrosis and myoﬁbroblasts proliferation
[35]. However, to date there are no studies analyzing the role of the
N-Ras isoform in the processes that trigger and regulate renal ﬁbro-
sis. For this reason, the purpose of the present study has been to as-
sess the effect of N-Ras deﬁciency in basal and TGF-β1-mediated
ECM synthesis, proliferation and migration in cultured embryonic ﬁ-
broblasts isolated from mice lacking the N-Ras isoform (N-ras−/−).
The Ras signaling pathways MEK/Erk and PI3K/Akt have also been
studied to elucidate their possible role in ECM synthesis, prolifera-
tion and migration in the absence of N-Ras.
2. Materials and methods
2.1. Materials and reagents
Crystal violet was from Fluka (Buchs, Switzerland). Rabbit anti-mouse
Akt 1/2 and rabbit anti-rat Erk1, and mouse anti-human phospho-Erk
antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA., USA.).
Rabbit anti-human phospho-Akt antibody was from Cell Signalling
Technology (Danvers, MA USA). Rabbit anti-mouse collagen type I and
ﬁbronectin antibodies, PVDFmembrane, Ras GTPase Elisa Kit andmagne-
sium lysis buffer (MLB)were fromUpstate Biotechnology (Waltham,MA,
USA). Mouse anti-human PCNA antibody was from BD-Transduction
Laboratories (San Jose, CA, USA). Rabbit anti-human Ki67 was obtained
from MD (Granada, Spain). Goat anti-rabbit Cy3 was from Jackson
Immunoresearch (West Grove, PA, USA). Goat anti-rabbit and anti-
mouse IgG (H + L) horseradish peroxidase (HRP) conjugated antibodies
and Dc protein assay were from BioRad (Hercules, CA, USA). Hoechst
33258was fromMolecular Probes (Barcelona, Spain). ECL chemilumines-
cence Western blotting system and Hyperﬁlm X-ray ﬁlm were from GE-
Healthcare (Chalfont St. Giles, United Kingdom). Tri-reagent was from
Molecular Research Center (Cincinnati, OH, USA). JetPEI transfection re-
agent was from Polyplus Transfection (Illkirch, France). TGF-β1 was
from R&D Systems (Minneapolis, MN, USA). U0126 and LY294002 were
from Calbiochem-Merk (Madrid, Spain). [3H] proline was from American
Radiolabelled Chemical (St. Louis, MO, USA). Fetal calf serum (FCS),
Dulbecco's modiﬁed Eagle's medium (DMEM) and trypsin solution
were from Gibco-Invitrogen (Grand Island, NY, USA). The sterile plastic
material used in cell culturewas fromNunc (Roskilde, Denmark). Cell cul-
ture inserts were from Falcon (Madrid, Spain). Wallac 1409 DSA liquid
scintillation counter was from Perkin Elmer (Waltham, MA, USA) and
Scion Image software was from Scion Corporation (Frederick, MD, USA).
All other reagents were of analytical grade and obtained from Sigma
Química (Madrid, Spain), and Merck (Madrid, Spain).
2.2. Cell culture and growth factor stimulation
WT and N-ras−/− mouse embryonic ﬁbroblasts were subcultured
and immortalized as previously reported [36]. Brieﬂy, N-Ras KO ﬁbro-
blasts (N-ras−/−) were cultured from N-ras−/−mouse embryos which
were recovered at day post coitum 15–17 and were treated with
trypsin-ethylenediaminetetraacetic acid (EDTA) 0.25% (Gibco-BRL,
Cheshire, UK) for 30 min before plating. Immortalized cultures that sur-
vived crisis after 15–20 passages were identiﬁed and cloned and their
genotypes reconﬁrmed by PCR analysis as previously reported [36].
Immortalized cells were grown in DMEM medium containing 10%
FCS and 100 U/mL penicillin/streptomycin at 37 °C, 5% CO2. ForWestern
blot and PCR analysis cells were seeded in 100 mm Petri dishes, for total
collagen measurements and proliferation studies cells were plated at
20,000 or 9000 cells/well in 24 well plates, respectively. When cultures
achieved 80–90% conﬂuence, cells were serum-starved for 24 h and
treatedwith active human recombinant TGF-β1 (1 ng/mL) or control ve-
hicle during 24 h in the absence of serum. When pharmacologicalinhibition was used, mitogen activated kinase/Erk kinase-1 (MEK-1) in-
hibitor U0126 (20 μM) or the PI3K inhibitor LY294002 (20 μM) were
added 30 min before TGF-β1 stimulation.
2.3. Crystal violet staining
Total cell number wasmeasured using a colorimetric method previ-
ously described [37]. Brieﬂy, cells in 24well plateswere ﬁxed for 10 min
with 10% glutaraldehyde, stained in 1% crystal violet solution for
2736 I. Fuentes-Calvo et al. / Biochimica et Biophysica Acta 1833 (2013) 2734–274430 min, dried overnight, dissolved with 10% acetic acid and optical
absorbance was measured at 595 nm, which was proportional to the
number of viable cells in each well.
2.4. Immunoﬂuorescence analysis of Ki67 expression
Nuclear Ki-67 staining indicates the proliferating cells [38]. Cells on
cover slips were ﬁxed with 4% paraformaldehyde, washed withFig. 2. Expression of ECM proteins in WT and N-ras−/− ﬁbroblasts. Collagen type α1 (A) and ﬁ
(D) protein expression evaluated by Western blot; total collagen synthesis (E) evaluated by [3H
expression in N-ras−/− ﬁbroblasts (F). Lower panels in A and B show a representative picture
representative blot of 6 (N-ras−/−)–42 (WT) experiments, performed under similar conditio
expressed as percentage over basal values (WT ﬁbroblasts in 0.5% FCS, 100%), and correspond t
Histograms in E represent themean ± SEM of 16 (N-ras−/−)-42 (WT) experiments expressed
Statistically signiﬁcant differences: *(p b 0.05) or **(p b 0.01) vs. WT ﬁbroblasts in bas
TGF-β1; @(p b 0.05) or @@(p b 0.01) vs. N-ras−/− ﬁbroblasts in basal conditions.phosphate buffer saline (PBS: 0.81% NaCl, 2.6 mM H2KPO4, 4.1 mM
HNa2PO4), permeabilized with 0.1% Triton X-100, blocked 30 min with
2% BSA in PBS, treated with PBS-0.05% Tween-20 for 10 min, incubated
for 2 h with rabbit anti-human Ki67 (dilution 1/50) in PBS, and incubat-
ed for 30 min with goat anti-rabbit Cy3 (1/1000) in PBS in a dark cham-
ber. Nuclei staining were performed by 5 min incubation with 3 μM
Hoechst 33258 in the dark. Confocal images were obtained using a
Zeiss Axiovert 200M microscope with a HeNe laser with 543-excitationbronectin (B) mRNA expression evaluated by RT-PCR; collagen type I (C) and ﬁbronectin
] proline incorporation; effect of N-Ras re-introduction on collagen type I and ﬁbronectin
of 4 (WT)–6 (N-ras−/−) different RT-PCR experiments. Lower panels in C and D show a
ns. Histograms in A–D represent the mean ± SEM of the optical density of the bands,
o the ratio ﬁbronectin or collagen/Erk 1/2 expression or GAPDH (used as loading control).
as percentage over basal values (WT ﬁbroblasts in 0.5% FCS, 100%), performed in triplicate.
al conditions; #(p b 0.01) or ##(p b 0.05) vs. WT ﬁbroblasts treated with 1 ng/mL
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images had identical parameters for intensity, pinhole aperture, etc.
2.5. Ras activation
Ras-GTP in total cell lysates (50 μg)was quantiﬁed by theRas activa-
tion ELISA assay Kit following the manufacturer's instructions. Ras GTP
activation is expressed in n-fold vs. control.
2.6. Western blot analysis
Western blot was performed as previously described [33]. Mem-
branes were incubated with the following antibodies: anti-Akt 1/2
(dilution: 1/1000), anti-Erk1 (1/10,000), anti-phospho-Erk (1/2000),
anti-phospho-Akt (1/1000), anti collagen type I (1/20,000), anti-Fig. 3.Effect ofMEK/Erk1/2 and PI3K/Akt inhibition on the expression of ECMproteins inWTand
I (A),ﬁbronectin (C) andphospho-Erk (E) protein expression evaluated byWestern blot; and ef
and phospho-Akt (F) protein expression evaluated byWestern blot. Lower panels in A–D show
ditions. A–D histograms represent the mean ± SEM of the optical density of the bands, expres
spond to the ratioﬁbronectin or collagen/Erk 1/2. Statistically signiﬁcant differences: *(p b 0.05
ﬁbroblasts treated with 1 ng/mL TGF-β1; @(p b 0.05) or @@(p b 0.01) vs. N-ras−/− ﬁbroblastﬁbronectin (1/30,000), anti-PCNA (1/5000) and anti-Ras (1/1000). We
used total Erk 1/2 levels as controls for protein loading because their
basal levels showed no differences between WT and N-ras−/− ﬁbro-
blasts after TGF-β1 treatment, as we had previously found in H-Ras
KO and H- and N-Ras double KO ﬁbroblasts [32,33], whereas other pro-
teins frequently used as loading controls (actin, tubulin) were affected
after TGF-β1 treatment.
2.7. Polymerase chain reaction
PCR was performed as previously described [33]. Primers: for mouse
ﬁbronectin, bp 79 to 99, 5′-ATG TGG ACC CCT CCT GAT AGT-3′, and bp
182 to bp 202, 5′-GCC CAG TGA TTT CAG CAA AGG-3′. For human
collagen type I (α1), bp 5292 to 3314, 5′-TGT TGC TGA AAG ACT ACC
TCG T-3′, and bp 5572 to 5594, 5′-CCT CCC ATG TTA AAT AGC ACC T-3′.N-ras−/−ﬁbroblasts. Effect of phospho-Erk inhibitionwith 20 μMU0126 on collagen type
fect of phospho-Akt inhibitionwith 20 μMLY294402 on collagen type I (B), ﬁbronectin (D)
a representative blot of 6 (N-ras−/−)-42 (WT) experiments, performed under similar con-
sed as percentage over basal values (WT ﬁbroblasts in 0.5% FCS, 100%); histograms corre-
) or **(p b 0.01) vs.WT ﬁbroblasts in basal conditions; #(p b 0.01) or ##(p b 0.05) vs.WT
s in basal conditions; $(p b 0.01) vs. N-ras−/− ﬁbroblasts treated with 1 ng/mL TGF-β1.
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GTA GGC CAT GAG GTC CAC CAC-3′. Cycling conditions for collagen I:
95 °C, 5 min, 40 cycles of 1 min 95 °C, 1 min 52 °C and 1 min 72 °C,
and an elongation cycle of 5 min 72 °C; for ﬁbronectin: 5 min 95 °C,
35 cycles of 1 min 95 °C, 1 min 61.6 °C, and 1 min 72 °C, and an elonga-
tion cycle of 5 min 72 °C; for GAPDH: 5 min 94 °C, 28 cycles of 1 min
94 °C, 1 min 60 °C, and 1.5 min 72 °C, and an elongation cycle of
5 min 72 °C, using a Bio-Rad Thermal Cycler. Ampliﬁed products were
analyzed by electrophoresis in 1.5% agarose gels.Fig. 4.WT and N-ras−/− ﬁbroblast proliferation and PCNA expression. Effect of TGF-β1 treatmen
phospho-Erk inhibition with 20 μMU0126 (B) and phospho-Akt inhibition with 20 μM LY29400
ment (1 ng/mL) (D), phospho-Erk inhibition with 20 μM U0126 (E) and phospho-Akt inhibition
grams in A–C represent the mean ± SEM of 8–32 (WT) and 8 (N-ras−/−) experiments, pe
ﬁbroblasts in 0.5% FCS, 100%). Lower panels in D–E show representative blots of 32 (WT)–8 (N
mean ± SEM of the optical density of the bands, expressed as percentage over basal values (W
(used as loading control). Statistically signiﬁcant differences: &(p b 0.01) vs. WT ﬁbroblasts 48
or ##(p b 0.05) vs. WT ﬁbroblasts treated with 1 ng/mL TGF-β1; @(p b 0.05) or @@(p b 0.01
with 1 ng/mL TGF-β1.2.8. Total collagen synthesis measurement
The incorporation of [3H]-proline into collagen proteins was used to
quantify collagen content in the culture medium, as described else-
where [39]. Radiolabeling was performed incubating 0.15 mM β-
aminopropionitrile, 210 mM ascorbic acid, 183 mM proline and 1 μCi/
well [3H]-Proline (speciﬁc activity: 40 Ci/mmol) for 24 h in fresh
DMEM serum-free medium. Proteins were precipitated in ice-cold 10%
trichloroacetic acid and the pellet was washed and resuspended int (1 ng/mL) on ﬁbroblasts proliferation measured at 24–48 h by crystal violet staining (A);
2 (C) on ﬁbroblasts proliferation evaluated by crystal violet staining; effect of TGF-β1 treat-
with 20 μM LY294002 (F) on PCNA protein expression evaluated by Western blot. Histo-
rformed in triplicate and expressed as percentage over basal values (WT and N-ras−/−
-ras−/−) experiments, performed under similar conditions and histograms represent the
T ﬁbroblasts in 0.5% FCS, 100%); bands correspond to the ratio PCNA/total Erk expression
h depleted; *(p b 0.05) or **(p b 0.01) vs. WT ﬁbroblasts in basal conditions; #(p b 0.01)
) vs. N-ras−/− ﬁbroblasts in basal conditions; $(p b 0.01) vs. N-ras−/− ﬁbroblasts treated
2739I. Fuentes-Calvo et al. / Biochimica et Biophysica Acta 1833 (2013) 2734–27440.1 N NaOH. [3H]-Proline incorporated into collagen proteins was mea-
sured in a β scintillation counter.
2.9. Wound-healing assay
In vitro scratched wounds were created with a straight incision on
serum-starved conﬂuent cell monolayers with a sterile disposable pi-
pette tip. Cell migration into denuded area was monitored over a time
course using digital microscopy and cell movement was calculated as
the reduction of the wound area over time (in percentage, initial area
of the wound: 100%).
2.10. Cell migration assay
Fibroblast migration was evaluated with a method based on the
Boyden assay as previously described [32]. Cell suspension in 2% FCS
medium was loaded into the chamber, and invading cells migrate
through and attach to an 8 μm pore size polycarbonate membrane
(bottom chamber containing 10% FCS medium), while non-invading
cells remain above. The number of cells in the bottom of the chamber
(migrating cells) was determined by the crystal violet method.
2.11. Cell transfection
N-Ras expression in N-ras−/− ﬁbroblasts was induced by transfec-
tion of the pcEFL NRAS plasmid encoding N-Ras [40]. Fibroblasts were
transfected for 20 h using JetPEI transfection reagent according to the
manufacturer's instructions. Then, the cells were grown in 0.5% FCS
DMEMmedium for 24 h and cells were lysed for Western blot analysis.
2.12. Statistical methods
Data are expressed as mean ± standard error of the mean (SEM).
The Kolmogorov–Smirnov test was used to assess the normality of the
data distribution. Comparison ofmeanswas performed by twoway anal-
ysis of variance (ANOVA) and Bonferroni post-test. Statistical differences
between groupswere assessed by the Student “t” test. Statistical analysis
was performed using Graph Pad Prism version 5.00 forWindows, Graph
Pad Software, SanDiego California USA,www.graphpad.com. A “p” value
lower than 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Activation of Ras and expression of Ras effectors, Erk and Akt
Total Ras expression levels, analyzed byWestern blot, were slightly
decreased in N-ras−/−with respect toWT ﬁbroblasts (data not shown).
To determine the effect of the absence of the N-Ras isoform on Ras acti-
vation, we analyzed cellular extracts fromWT and N-ras−/− ﬁbroblasts
in basal conditions and under TGF-β1 treatment with Ras activation
ELISA assay Kit. Basal Ras activation was slightly increased in N-ras−/−
with respect to WT ﬁbroblasts. Treatment with 1 ng/mL TGF-β1 for
24 h did not increase signiﬁcantly Ras activation in ﬁbroblasts (Fig. 1A).
We also analyzed byWestern blot possible changes in the activation
of MEK/Erk and PI3K/Akt pathways. The ratio phospho-Erk/Erk and
phospho-Akt/Akt was signiﬁcantly higher in basal conditions in N-Ras
KO ﬁbroblasts than in WT ﬁbroblasts. TGF-β1 treatment for 24 h in-
creased these ratios in WT ﬁbroblasts, but no effect was observed in
N-ras−/− ﬁbroblasts (Fig. 1B and C).
3.2. ECM proteins synthesis in ﬁbroblasts
In order to evaluate thepossible differences in the expression of ECM
proteins in the absence of the N-Ras isoform, we analyzed by RT-PCR
andWestern blot the basal and TGF-β1-induced expression of ﬁbronec-
tin and collagen type I in both N-ras−/− and WT ﬁbroblasts. Wepreviously performed a collagenase assay to elucidate which bands
correspond to collagen, and thus 180 and 90 kDa bands were identiﬁed
and quantiﬁed in order to measure collagen type I expression [33]. We
also evaluated the synthesis of total collagen proteins by measuring
[3H]-proline incorporation into collagen proteins. Dose and time for
TGF-β1 treatment (1 ng/mL, 24 h) was based on previous studies
[32,33].
In basal conditions, collagen type I mRNA and protein expression, as
well as total collagen synthesis, were signiﬁcantly higher in N-ras−/−
ﬁbroblasts than inWT ﬁbroblasts (Fig. 2A, C and E). Fibronectin protein
expression was similar in both WT and N-ras−/− ﬁbroblasts, but
ﬁbronectin mRNA expression was higher in absence of N-Ras (Fig. 2B
and D). TGF-β1 increased total collagen synthesis as well as collagen
type I and ﬁbronectin expression (Fig. 2A–D). However, in N-ras−/−
ﬁbroblasts TGF-β1 did not induce any signiﬁcant increase in total
collagen synthesis with respect to the same cells in basal conditions
(Fig. 2E). On the other hand, transfection with a plasmid containing
N-Ras-encoding DNA in N-Ras KO ﬁbroblasts induced a decrease in
the expression of ECM proteins collagen I and ﬁbronectin (Fig. 2F).
To assess the putative role of MEK/Erk and PI3K/Akt pathways in the
regulation of ECM proteins expression in the absence of the N-Ras iso-
form, we analyzed the effect of their inhibition on both basal and TGF-
β1-induced ﬁbronectin and collagen I expression in N-ras−/− and WT
ﬁbroblasts by co-incubating the cells with the MEK 1/2 inhibitor
U0126 (20 μM) or with the PI3K inhibitor LY294002 (20 μM) for 24 h.
Basal expression of both collagen I andﬁbronectinwere signiﬁcantly re-
duced after Erk inhibition in WT ﬁbroblasts but this reduction was not
statistically signiﬁcant in N-ras−/− ﬁbroblasts (Fig. 3A and C). The inhi-
bition of Erk phosphorylation induced a signiﬁcant reduction in TGF-β1-
induced ﬁbronectin expression inWT ﬁbroblasts (Fig. 3C), but it did not
modify TGF-β1-induced collagen I or ﬁbronectin expression in ﬁbro-
blasts lacking N-Ras (Fig. 3A and C). PI3K inhibition signiﬁcantly re-
duced both basal and TGF-β1-induced expression of collagen type I in
bothWT and N-ras−/− ﬁbroblasts (Fig. 3B), but it did not modify signif-
icantly neither basal nor TGF-β1-induced ﬁbronectin expression in both
types of ﬁbroblasts (Fig. 3D). The effect of both inhibitors on Erk and Akt
phosphorylation is shown in Fig. 3E and F.3.3. Fibroblast proliferation
Weevaluated the role of theN-Ras isoform in ﬁbroblast proliferation
analyzing a) the total number of cells by nuclear stainingwith crystal vi-
olet, b) expression of Ki67 – a protein expressed during G1, S, G2 andM
cell cycle phases [41] – and c) expression of PCNA – a component of rep-
lication and DNA repairing machinery [42]. Fibroblasts proliferation
during 24 and 48 h, measured as the total number of cells, was signiﬁ-
cantly lower in N-ras−/− than in WT ﬁbroblasts (Fig. 4A); moreover,
PCNA expression (Fig. 4E) and the number of Ki67-possitive cells
(Fig. 5A) after 24 h were also lower in N-ras−/− than in WT ﬁbroblasts.
We also determined the effect of TGF-β1 treatment on cell prolifer-
ation. TGF-β1 (1 ng/mL, 48 h) increased ﬁbroblast proliferation in
both N-ras−/− and WT ﬁbroblasts, (Fig. 4A). However, TGF-β1 induced
increases inKi67 and PCNAexpressions only inWTﬁbroblasts but not in
N-ras−/− ﬁbroblasts (Figs. 4D and 5A).
We analyzed the effect of MEK and PI3K inhibition in TGF-β1-
induced ﬁbroblast proliferation by co-incubation with the MEK 1/2 in-
hibitor U0126 (20 μM) or with the PI3K inhibitor LY294002 (20 μM)
for 24 h. PI3K inhibition reduced basal and TGF-β1-induced ﬁbroblast
proliferation, as well as Ki67 expression in WT and KO cells, although
PCNA expressionwas not reduced after PI3K inhibition in KO ﬁbroblasts
(Figs. 4C, F and 5C). MEK inhibition only inhibited PCNA expression in
WT ﬁbroblasts (Fig. 4E), whereas TGF-β1-induced Ki67 expression
was also reduced in the presence of the MEK inhibitor in both WT and
KO cells (Fig. 5B); MEK inhibition did not induce any change in either
basal or TGF-β1 induced ﬁbroblast proliferation (Fig. 4B).
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Fibroblast migration was analyzed measuring the reduction in the
wound area for 20 h in an in vitro wound-healing assay and by deter-
mining cell migration by use of a Boyden chamber. Time-course studies
of wound closure area showed that cell movement in N-ras−/− ﬁbro-
blasts was notably slower than in WT cells (Fig. 6A and B); moreover,
ﬁbroblast migration in Boyden chamber was also markedly decreased
in N-ras−/− ﬁbroblasts with respect to WT ﬁbroblasts (Fig. 6E). There-
fore, cell movement seems to be signiﬁcantly restricted in ﬁbroblasts
lacking N-Ras.
Erk inhibition did not modify wound closure time in a signiﬁcant
manner in either N-ras−/− or WT ﬁbroblasts (Fig. 6C), but decreased
the number of migrating cells through the Boyden chamber in N-ras−/−
ﬁbroblasts (Fig. 6E). Akt inhibition increased wound closure times in
WT ﬁbroblasts to values similar to those of N-ras−/− ﬁbroblasts
(Fig. 6D) and reduced cellular migration through the Boyden chamber
in both N-ras−/− and WT ﬁbroblasts (Fig. 6E).
3.5. Effect of N-Ras knock-down in a different ﬁbroblast cell clone
We performed additional experiments with a second N-Ras KO cell
clone of immortalized ﬁbroblasts. Supplementary Fig. 1 shows that the
effect of the absence of N-Ras on ﬁbroblast proliferation and in the ex-
pression of extracellular matrix proteins is similar to that observed in
the previous studied clone. All these data seem to conﬁrm that the ef-
fects observed in the absence of N-Ras are not due to the selection of a
particular clone.
4. Discussion
Ras GTPase family members are crucial players in a variety of pro-
cesses as cell proliferation, migration, or cytoskeletal changes [43,44].
Although there are several papers describing the relationships between
Ras proteins and their effectors Erk and Akt, and in vivo renal ﬁbrosis,
including some from our group [45,46], this is the ﬁrst study assessing
the involvement of the N-Ras isoform and some intracellular
pathways (MEK/Erk and PI3K/Akt) in ﬁbroblast function and ﬁbrosis
development.
Loss of the ECMhomeostasis is one of themain features of theﬁbrotic
processes [47,48] andﬁbroblasts play amajor role inﬁbrosis [30].Weob-
served a higher accumulation of one of the main ECM protein (collagen)
in cultured ﬁbroblasts without the N-Ras isoform than inWT ﬁbroblasts,
suggesting a possible modulator role of N-Ras in this process. Moreover,
transfectionwith a plasmid containingN-Ras-encodingDNA inN-Ras KO
ﬁbroblasts decreased the expression of collagen I and ﬁbronectin. It has
been reported that N-Ras activation decreased mRNA expression of col-
lagen type I genes in rat ﬁbroblasts [49] and ﬁbronectin accumulation in
a human ﬁbrosarcoma cell line [50–53].We suggest that in unstimulated
ﬁbroblasts N-Ras probably acts either as a negative regulator of genes
transcription pathways or as an activator of degrading enzymes forﬁbro-
nectin and collagen type I, although the regulation of TGF-β1-induced
collagen I and ﬁbronectin expression seems to be N-Ras independent.
Fibronectin expression is similar either in the presence or absence of
N-Ras. However, our group has previously observed a decrease in ﬁbro-
nectin expression in ﬁbroblasts lacking both H- and N-Ras [33], which
suggests that ﬁbronectin expression in basal conditions appears to be
H-Ras dependent and independent of the presence of N-Ras.
The higher ECM accumulation observed in N-Ras KO ﬁbroblasts
may be related with the higher activation of phospho-Erk andFig. 5. Ki67 expression inWT and N-ras−/− ﬁbroblasts. Effect of TGF-β1 treatment (1 ng/mL) (A
LY294002 (C) onKi67 expression evaluatedby inmmunoﬂuorescence. Lower panels inA show r
performed under similar conditions. Histograms represent the mean ± SEM of 33 (WT)-11 (
Hoechst stained cells (blue). Statistically signiﬁcant differences: *(p b 0.05) or **(p b 0.01) vs.
with 1 ng/mL TGF-β1; @(p b 0.05) or @@(p b 0.01) vs. N-ras−/− ﬁbroblasts in basal conditionphospho-Akt detected in those ﬁbroblasts in basal conditions. Inhibi-
tion of Erk activation reduced collagen I and ﬁbronectin expression
in WT but not in N-ras−/− ﬁbroblasts and did not induce signiﬁcant
changes in TGF-β1-induced collagen and ﬁbronectin expression,
suggesting that Erk activation is involved in ECM accumulation in
basal conditions although the N-Ras isoform may be modulating
collagen I and ﬁbronectin expression through Erk-independent
pathways. Although N-Ras KO ﬁbroblasts show a higher phospho-
Erk expression in basal conditions than WT ﬁbroblasts, we have pre-
viously observed that H-Ras KO ﬁbroblasts show no changes in
phospho-Erk expression [32] and on the other hand, H- and N-Ras
double KO ﬁbroblasts exhibit signiﬁcantly lower phospho-Erk levels
than their WT controls [33], thus suggesting that phospho-Erk basal
expression is differently regulated by each of the Ras isoforms. On
the other hand, the implication of the PI3K/Akt pathway in ECM syn-
thesis regulation is widely described in many cell lines [54–57] and
in in vitro models of renal tubule-interstitial ﬁbrosis [45]. Our data
in WT and N-ras−/− ﬁbroblasts agree with these studies and suggest
that phospho-Akt expression is, at least partially, dependent of N-Ras
isoform, which may down-regulate ECM accumulation through inhi-
bition of Akt activation. These ﬁndings are in concordance with our
previous studies showing that both N- and H-Ras isoforms may pre-
vent the excessive ECM synthesis through down-regulation of PI3K/
Akt activity in ﬁbroblasts [32,33].
Fibroblast proliferation and migration are key processes in the de-
velopment of renal ﬁbrosis [30,31]. We observed that N-ras−/− ﬁbro-
blasts showed less PCNA and Ki67 protein expressions and less
proliferation thanWTﬁbroblasts after 24 h in basal conditions. Reduced
ﬁbroblast proliferation may be related with the higher ECM production
observed in N-ras−/− ﬁbroblasts, as it was previously described by
Weber and cols. in a tumoral pancreatic cell line [58]. It has been report-
ed that TGF-β stimulates proliferation of ﬁbroblasts [59–63]. Our results
suggest that this proliferative effect induced by TGF-β is independent of
N-Ras. In an in vivo study, early ﬁbrotic changes induced by unilateral
ureteral ligationwere similar in N-ras−/− and inWTmice [64]. It should
be noted that in early ﬁbrotic changes after unilateral ureteral ligation,
the participation of renal myoﬁbroblasts is very limited [64]. Activation
of Erk and Akt pathways may up- or down-regulate proliferation in
many cell lines and in vitro models depending of the cell state and the
signal duration. Generally, Erk activation increases proliferation
[65–67]. However in proliferating cells, a high activation of the Erk
pathwaymay induce cell cycle stop¸ senescence, apoptosis and differen-
tiation, but a sustained and low activation of the Erk pathway is a
normal feature of numerous proliferating systems [68–71]. PI3K activa-
tion also induces proliferation in renal ﬁbroblasts [57], in NIH3T3 ﬁbro-
blast treated with Wnt3a protein [72] and in lung ﬁbroblast stimulated
with ionic radiation [73]. In our study, ﬁbroblast proliferation is
inhibited by LY294002 in both WT and N-ras−/− ﬁbroblasts and Erk
inhibition reverts TGF-β1-induced-proliferation only in WT ﬁbroblasts,
although TGF-β1-induced PCNA expression did not change in N-ras−/−
ﬁbroblasts after Erk or Akt inhibition. Basal phospho-Erk levels are elevat-
ed in the absence of N-Ras, and these elevated levelsmay explain that the
phospho-Erk inhibitor U0126 is not capable of reducing phospho-Erk
levels low enough to affect the rate of cell proliferation. However, it is
striking that phospho-Erk, a intracellular mediator usually involved in
signaling pathways associated with stimulation of proliferation, is elevat-
ed in N-Ras KO ﬁbroblasts, and these cells present a less proliferation in
response to TGF-β1. This fact seems to suggest that TGF-β1-induced pro-
liferation appears not to be phospho-Erk dependent in this cell type. On
the other hand, previous studies from our group showed that TGF-β1-), phospho-Erk inhibition with 20 μMU0126 (B) and phospho-Akt inhibition with 20 μM
epresentativemicrophotographs (100×)of Ki67 immunostainingof different experiments,
N-ras−/−) different ﬁelds analyzed, expressed as percentage of Ki67 stained cells (red)/
WT ﬁbroblasts in basal conditions; #(p b 0.01) or ##(p b 0.05) vs. WT ﬁbroblasts treated
s; $(p b 0.01) vs. N-ras−/− ﬁbroblasts treated with 1 ng/mL TGF-β1.
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blasts than in WT [29], which seems to conﬁrm that the proliferative
processes are mostly H-Ras dependent. Thus, most of our data sug-
gest that Akt-mediated proliferation is independent of the presence
of N-Ras, but N-Ras might modulate TGF-β1 induced-proliferation
through phospho-Erk expression. The discrepancy found between
the increased number of viable cells and PCNA and Ki67 expressions
in response to TGF-β1 treatment may be due to the effect of N-Ras
deﬁciency, but further experiments are needed to identify other
proliferation-related intracellular pathways that are offsetting this
effect.
We also show that N-Ras modulates ﬁbroblast mobility. Previously,
Fotiadou et al. [34] described a different modulating role of N-Ras and
K-Ras proteins in ﬁbroblast migration, showing that ﬁbroblasts lacking
N-Ras or K-Ras do not drive a correct cell migration and suggesting
that N-Ras is more relatedwith adhesion pathways. Our results conﬁrm
these data because N-Ras KO ﬁbroblasts required more time to com-
plete in vitro healing and to migrate through Boyden chambers. On
the other hand, Akt inhibition (but not Erk inhibition) reduced migra-
tion inWT cells, suggesting themediation of the PI3K/Akt pathway in ﬁ-
broblast migration. In N-ras−/− ﬁbroblasts the inhibition of Akt or Erk
do not have any effect in postscratching closure-time, probably due to
the lower migration rate of these cells in basal conditions, and also
due to the fact that both cell proliferation and migration are involved
in the closure time in cell wound assay. Nevertheless, Akt inhibition re-
duced the number of migrating cells through the Boyden chamber in
both WT and N-ras−/− ﬁbroblasts, but Erk inhibition only decreased
the number of migrating N-ras−/− ﬁbroblasts. These results evidence
the involvement of Akt (and to a lesser extent, Erk) pathways in the reg-
ulation of ﬁbroblast migration, although their relation with N-Ras are
not sufﬁciently enlightened in this experimental model.
In conclusion, we described amodulator role of the N-Ras isoform in
three of the main ﬁbrotic processes in ﬁbroblasts: ECM synthesis,
proliferation and migration. In resting conditions, ﬁbroblasts lacking
N-Ras synthesize larger amounts of ECM and show reduced motility
and reduced proliferative rate with a higher activation of Akt and Erk
than WT ﬁbroblasts. Our data suggest that in unstimulated cells, N-Ras
might down-regulate Akt activation, reduce ECM accumulation and
maintain normal proliferation and migration rates. N-Ras also medi-
ates TGF-β1-induced collagen I and ﬁbronectin expression through
Erk-independent pathways, although TGF-β1 induced proliferation
seems to be independent of N-Ras but modulated by Erk and Akt.
Further experiments are needed to identify the crosstalk between
the different signaling pathways induced by the activation of every
Ras isoform.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2013.07.008.
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